

PRECEPTORSHIP PROGRAMME

Immuno-Oncology

From the essentials of tumour
immunology to clinical application

**ESMO VIRTUAL
PRECEPTORSHIP**

16-17 DECEMBER 2020

Co-Chairs

John B.A.G. Haanen, Netherlands
Solange Peters, Switzerland
Rolf A. Stahel, Switzerland

ESMO VIRTUAL PRECEPTORSHIP PROGRAMME

IMMUNO-ONCOLOGY

From the essentials of tumour immunology to clinical application

16-17 December 2020

CO-CHAIRS:

John B.A.G. Haanen, Netherlands
Solange Peters, Switzerland
Rolf A. Stahel, Switzerland

SPEAKERS:

Fabrice André, France
Paolo A. Ascierto, Italy
Andrés Cervantes, Spain
Mitchell Levesque, Switzerland
Markus Manz, Switzerland
Michel Obeid, Switzerland
Camillo Guglielmo Porta, Italy
Cristiana Sessa, Switzerland

LEARNING OBJECTIVES

- To understand the basics of tumour immunology
- To learn about the essentials of immunotherapies and their applications in cancer medicine
- To learn about the status of development and clinical experience of immunotherapy in different tumour types

ACCREDITATION

The programme of this event has been accredited with **6 ESMO-MORA category 1 points**. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



All timings are to be considered CET (Central European Time)

Wednesday, 16 December 2020

15:00-15:05 5'	Opening and welcome	John B.A.G. Haanen, NL Solange Peters, CH Rolf A. Stahel, CH
15:05-16:20 75'	SESSION 1 Essentials in immunotherapies	Chair/Moderator: John B.A.G. Haanen, NL
20'	Developments in Immunotherapy	Paolo A. Ascierto, IT
20'	Developments in Biomarkers	Mitchell Levesque, CH
20'	Management of toxicities	Michel Obeid, CH
15'	Discussion	Faculty
16:20-16:30	Break	
16:30-17:25 55'	SESSION 2 Clinical development	Chair/Moderator: Solange Peters, CH
20'	Melanoma: Immune Checkpoints & Combination therapies	John B.A.G. Haanen, NL
20'	Immunotherapy of Gastro-Intestinal cancers	Andrés Cervantes, ES
15'	Discussion	Faculty
17:25-18:20 55'	SESSION 3 Clinical development	Chair: Rolf A. Stahel, CH
20'	Gynaecological malignancies	Cristiana Sessa, CH
20'	Haemato-oncology	Markus Manz, CH
15'	Discussion	Faculty

Thursday, 17 December 2020

09:00-09:55 55'	SESSION 4 Clinical development	Chair/Moderator: Solange Peters, CH
20'	Breast cancer	Fabrice André, FR
20'	Bladder and renal cell cancer	Camillo Guglielmo Porta, IT
15'	Discussion	Faculty
09:55-10:50 55'	SESSION 5 Lung cancer and thoracic cancer	Chair/Moderator: John B.A.G. Haanen, NL
20'	Advanced Non-Small-Cell Lung Cancer (NSCLC)	Solange Peters, CH
20'	Early stage NSCLC, SCLC and mesothelioma	Rolf A. Stahel, CH
15'	Discussion	Faculty

10:50-11:00	Break	
11:00-11:40 40'	SESSION 6 Audience cases	Chair/Moderator: Rolf A. Stahel, CH
40'	Participants clinical case discussion (4x10')	Faculty
11:40-12:00 20'	General discussion & Closing	John B.A.G. Haanen, NL Solange Peters, CH Rolf A. Stahel, CH

Note: Each 10-minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion